FDA Approves New First-in-Class Narcolepsy Medication Orzeyful

The FDA has granted approval to Takeda's Orzeyful, a novel first-in-class drug designed to treat narcolepsy type 1. This medication is notable for targeting the disease's underlying biology, aiming to improve wakefulness, reduce cataplexy, and alleviate other symptoms like sleep paralysis and disrupted nighttime sleep. The approval offers a new treatment option for patients with this chronic neurological condition.